What Happened
Mounjaro, a newly approved weight loss drug, has gained attention for its efficacy in treating type 2 diabetes and aiding in chronic weight management. The drug, which is a self-administered injection, received regulatory approval in December of last year and is now available by prescription in some pharmacies in New Zealand. Reports indicate that Mounjaro targets two hormones, enhancing its effectiveness compared to other weight-loss medications like Wegovy, which targets only one hormone.
Why It Matters
According to obesity doctor Dr. Chaey Leem, patients using Mounjaro have experienced an average weight loss of 22% at maximum doses, compared to 15% with Wegovy. However, the high cost of Mounjaro, ranging from $430 to nearly $900 per month, poses a significant barrier for many patients. Dr. Leem expressed hope that increased competition in the market could improve accessibility for those in need, despite the ongoing stigma surrounding obesity.
What’s Next
In addition to the challenges posed by cost, there are growing concerns about the proliferation of counterfeit versions of Mounjaro and other weight-loss drugs. Reports indicate that scammers are cloning reputable online pharmacies to sell dangerous fake versions of these medications. Experts, including Sehar Shadid, have warned that these illegal sales are putting vulnerable patients at risk. As the market for weight-loss drugs evolves, it will be crucial for consumers to remain vigilant and informed about the legitimacy of the products they purchase.